home / stock / aavxf / aavxf articles
No one has written and article on Abivax SA, stock symbol AAVXF. Be the first to contribute and write an article.
News, Short Squeeze, Breakout and More Instantly...
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025 Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with ...
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabi...
PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients...